Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case series

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2020 · 595 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

Jonathan I. Silverberg, D. Toth, Thomas Bieber et al. · British Journal of Dermatology · 2020 · 317 citations · Full text

Medicine, Dermatology, Immunology +17

Updated<scp>S2</scp>K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>)

Luca Borradori, Nina van Beek, Claudio Feliciani et al. · Journal of the European Academy of Dermatology and Venereology · 2022 · 253 citations · Full text

Medicine, Dermatology, Pathology +16

Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series

Rana Abdat, Reid A. Waldman, Valeria De Bedout et al. · Journal of the American Academy of Dermatology · 2020 · 202 citations

Veterinary Medicine, Pathobiology, Population Medicine +4

Pathophysiologic mechanisms of itch in bullous pemphigoid

Takashi Hashimoto, Christina Kursewicz, Rachel Fayne et al. · Journal of the American Academy of Dermatology · 2019 · 112 citations

Veterinary Medicine, Pathobiology, Herpetology +6